Drug Profile

KFP H013

Alternative Names: H 013; KFP-H013

Latest Information Update: 28 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Carephar Pharmaceutical
Class Antineoplastics; Small molecules
Mechanism of Action TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Oct 2025 No recent reports of development identified for preclinical development in Cancer in China
28 Sep 2021 Preclinical trials in Cancer in China (unspecified route) before September 2021 (Jiangsu Carephar Pharmaceutical pipeline, September 2021)
28 Sep 2021 Jiangsu Carephar Pharmaceutical plans to submit IND application for Cancer in USA and China in 2021 (Jiangsu Carephar Pharmaceutical pipeline, September 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com